WuXi AppTec Co Ltd
SSE:603259

Watchlist Manager
WuXi AppTec Co Ltd Logo
WuXi AppTec Co Ltd
SSE:603259
Watchlist
Price: 55.69 CNY -1.35% Market Closed
Market Cap: 160.8B CNY
Have any thoughts about
WuXi AppTec Co Ltd?
Write Note

WuXi AppTec Co Ltd
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

WuXi AppTec Co Ltd
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
WuXi AppTec Co Ltd
SSE:603259
Gross Profit
¥15.3B
CAGR 3-Years
25%
CAGR 5-Years
27%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Gross Profit
¥3.9B
CAGR 3-Years
17%
CAGR 5-Years
28%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Gross Profit
¥6.6B
CAGR 3-Years
18%
CAGR 5-Years
39%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Gross Profit
¥2.5B
CAGR 3-Years
8%
CAGR 5-Years
15%
CAGR 10-Years
26%
M
MGI Tech Co Ltd
SSE:688114
Gross Profit
¥1.5B
CAGR 3-Years
-10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
W
WuXi XDC Cayman Inc
HKEX:2268
Gross Profit
¥559.6m
CAGR 3-Years
310%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

WuXi AppTec Co Ltd
Glance View

Market Cap
162.2B CNY
Industry
Life Sciences Tools & Services

In the bustling corridors of global pharmaceuticals, WuXi AppTec Co Ltd. emerges as a vital bridge between expansive scientific potential and the practical demands of drug development. Founded in China, WuXi AppTec began its journey by transforming itself into a leading provider of R&D and manufacturing services to the pharmaceutical, biotech, and healthcare industries. With a broad portfolio that spans from the initial stages of drug discovery to the intricate processes of commercial production, WuXi AppTec offers an integrated platform to its clients. This platform allows global pharmaceutical companies, fledgling biotech firms, and even academic institutions to streamline their research initiatives, reduce development timelines, and ultimately bring therapeutic innovations to the market more efficiently. The company's business model thrives on its "one-stop-shop" approach, which is comprised of client-tailored solutions that address every stage of the drug development lifecycle. WuXi generates revenue through a variety of services, including laboratory testing, clinical trial support, and large-scale manufacturing. By leveraging its comprehensive capabilities in chemistry, biologics, and genomics, it successfully caters to a diversified clientele, ensuring sustainability through a steady stream of contract-based income. With an emphasis on advanced technologies and a global footprint that covers North America, Europe, and Asia, WuXi AppTec stands as a crucial ally to innovators ardently seeking to overcome the challenges of modern medicine by expediting the path from ‘concept’ to ‘cure’.

Intrinsic Value
88.23 CNY
Undervaluation 37%
Intrinsic Value
Price

See Also

What is WuXi AppTec Co Ltd's Gross Profit?
Gross Profit
15.3B CNY

Based on the financial report for Sep 30, 2024, WuXi AppTec Co Ltd's Gross Profit amounts to 15.3B CNY.

What is WuXi AppTec Co Ltd's Gross Profit growth rate?
Gross Profit CAGR 5Y
27%

Over the last year, the Gross Profit growth was -4%. The average annual Gross Profit growth rates for WuXi AppTec Co Ltd have been 25% over the past three years , 27% over the past five years .

Back to Top